ArticleCancer research2019

ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.

Beth Apsel Winger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.